Glucotrack (Nasdaq:GCTK) today provided an update on the planned regulatory timeline for its continuous blood glucose monitor ...
Acumen Pharmaceuticals (NASDAQ:ABOS) outlined progress across its lead Alzheimer’s disease program and an emerging “enhanced ...
Chronic disease management stands at an inflection point. Globally, the number of people living with diabetes continues to climb, and healthcare systems in both developed and emerging markets are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results